An Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) with Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy